Krystal Biotech (KRYS) Finished Goods (2023 - 2026)

Krystal Biotech has reported Finished Goods for 4 years, with the latest figure at $9.4 million in Q2 2026.

• Finished Goods for Q2 2026 came in at $9.4 million, up 449.62% year-over-year; the trailing twelve-month figure through Jun 2026 was $9.4 million (up 449.62% YoY), and the FY2025 annual result was $9.3 million, up 338.05% from the prior year.
• Finished Goods retreated to $9.4 million in Q2 2026, from $12.4 million in the prior quarter.
• Over five years, Finished Goods peaked at $12.4 million in Q1 2026 and troughed at $161000.0 in Q1 2024.
• A 4-year average of $4.9 million and a median of $3.2 million in 2024 frame the typical range for Finished Goods.
• The largest YoY upside for Finished Goods was 3563.35% in 2025 against a maximum downside of 4.03% in 2025.
• A 4-year view of Finished Goods shows it stood at $627000.0 in 2023, then surged by 239.07% to $2.1 million in 2024, then soared by 338.05% to $9.3 million in 2025, then climbed by 0.5% to $9.4 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $9.4 million in Q2 2026, $12.4 million in Q1 2026, and $9.3 million in Q4 2025.